Please sign in to follow a disease.
Mitochondrial oxidative phosphorylation disorder
MONDO:0016387A multisystem disorder with variable manifestations resulting from a defect in the mitochondrial oxidative phosphorylation (OXPHOS) system.
Also known as: OXPHOS disease, OXPHOS system deficiency
63 clinical trials for this condition and its sub-types, 3 tagged with Mitochondrial oxidative phosphorylation disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mitochondrial oxidative phosphorylation disorder
-
Leber hereditary optic neuropathy 18 trials
1 sub-type
- Leber optic atrophy and dystonia 0 trials
-
Mitochondrial DNA depletion syndrome 3 trials · 11 incl. sub-types
21 sub-types
- Mitochondrial DNA depletion syndrome, hepatocerebral form 0 trials · 4 incl. sub-types Sub-types →
- Mitochondrial DNA depletion syndrome, myopathic form 4 trials
- AFG3L2-related optic atrophy and/or spastic ataxia spectrum 0 trials Sub-types →
- Sengers syndrome 0 trials
- Mitochondrial DNA deletion syndrome with progressive myopathy 0 trials
- Mitochondrial DNA depletion syndrome 1 0 trials
- Mitochondrial DNA depletion syndrome 11 0 trials
- Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominant 0 trials
- Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessive 0 trials
- Mitochondrial DNA depletion syndrome 14B (cardioencephalomyopathic type) 0 trials
- Mitochondrial DNA depletion syndrome 15 (hepatocerebral type) 0 trials
- Mitochondrial DNA depletion syndrome 16 (hepatic type) 0 trials
- Mitochondrial DNA depletion syndrome 17 0 trials
- Mitochondrial DNA depletion syndrome 18 0 trials
- Mitochondrial DNA depletion syndrome 19 0 trials
- Mitochondrial DNA depletion syndrome 20 (mngie type) 0 trials
- Mitochondrial DNA depletion syndrome 4b 0 trials
- Mitochondrial DNA depletion syndrome, encephalomyopathic form 0 trials Sub-types →
- Mitochondrial dna depletion syndrome 14A (encephalomyopathic type) 0 trials
- Mitochondrial dna depletion syndrome 16B (neuroophthalmic type) 0 trials
- Mitochondrial dna depletion syndrome 21 0 trials
-
Leigh syndrome 9 trials
4 sub-types
-
Kearns-Sayre syndrome 5 trials
-
Mitochondrial respiratory chain complex deficiency 4 trials · 5 incl. sub-types
9 sub-types
- Mitochondrial complex I deficiency 2 trials Sub-types →
- Mitochondrial complex IV deficiency, nuclear-type 1 trial Sub-types →
- SDHC-related Mitochondrial Disease 0 trials
- Mitochondrial complex III deficiency 0 trials Sub-types →
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4B 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 5 0 trials
-
Deafness, aminoglycoside-induced 4 trials
-
NARP syndrome 3 trials
-
Coenzyme Q10 deficiency 3 trials
10 sub-types
- COQ7-related distal hereditary motor neuropathy 0 trials
- Autosomal recessive ataxia due to ubiquinone deficiency 0 trials
- Coenzyme Q10 deficiency, primary, 1 0 trials
- Coenzyme Q10 deficiency, primary, 3 0 trials
- Coenzyme q10 deficiency, primary, 9 0 trials
- Deafness-encephaloneuropathy-obesity-valvulopathy syndrome 0 trials
- Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome 0 trials
- Primary coenzyme Q10 deficiency 8 0 trials
-
3 sub-types
-
Ataxia neuropathy spectrum 2 trials
2 sub-types
-
Pontocerebellar hypoplasia type 6 2 trials
-
Leber plus disease 1 trial · 2 incl. sub-types
2 sub-types
-
Hereditary spastic paraplegia 7 1 trial
-
Charcot-Marie-Tooth disease type 4K 0 trials
-
Perrault syndrome 0 trials
7 sub-types
- Perrault syndrome 1 0 trials
- Perrault syndrome 2 0 trials
- Perrault syndrome 3 0 trials
- Perrault syndrome 4 0 trials
- Perrault syndrome 5 0 trials
- Perrault syndrome 6 0 trials
- Perrault syndrome 7 0 trials
-
58 sub-types
- Combined oxidative phosphorylation defect type 11 0 trials
- Combined oxidative phosphorylation defect type 13 0 trials
- Combined oxidative phosphorylation defect type 14 0 trials
- Combined oxidative phosphorylation defect type 15 0 trials
- Combined oxidative phosphorylation defect type 17 0 trials
- Combined oxidative phosphorylation defect type 2 0 trials
- Combined oxidative phosphorylation defect type 20 0 trials
- Combined oxidative phosphorylation defect type 21 0 trials
- Combined oxidative phosphorylation defect type 23 0 trials
- Combined oxidative phosphorylation defect type 24 0 trials
- Combined oxidative phosphorylation defect type 25 0 trials
- Combined oxidative phosphorylation defect type 26 0 trials
- Combined oxidative phosphorylation defect type 27 0 trials
- Combined oxidative phosphorylation defect type 30 0 trials
- Combined oxidative phosphorylation defect type 4 0 trials
- Combined oxidative phosphorylation defect type 7 0 trials
- Combined oxidative phosphorylation defect type 8 0 trials
- Combined oxidative phosphorylation defect type 9 0 trials
- Combined oxidative phosphorylation deficiency 19 0 trials
- Combined oxidative phosphorylation deficiency 28 0 trials
- Combined oxidative phosphorylation deficiency 29 0 trials
- Combined oxidative phosphorylation deficiency 32 0 trials
- Combined oxidative phosphorylation deficiency 33 0 trials
- Combined oxidative phosphorylation deficiency 34 0 trials
- Combined oxidative phosphorylation deficiency 35 0 trials
- Combined oxidative phosphorylation deficiency 36 0 trials
- Combined oxidative phosphorylation deficiency 37 0 trials
- Combined oxidative phosphorylation deficiency 38 0 trials
- Combined oxidative phosphorylation deficiency 39 0 trials
- Combined oxidative phosphorylation deficiency 40 0 trials
- Combined oxidative phosphorylation deficiency 41 0 trials
- Combined oxidative phosphorylation deficiency 42 0 trials
- Combined oxidative phosphorylation deficiency 43 0 trials
- Combined oxidative phosphorylation deficiency 44 0 trials
- Combined oxidative phosphorylation deficiency 45 0 trials
- Combined oxidative phosphorylation deficiency 46 0 trials
- Combined oxidative phosphorylation deficiency 47 0 trials
- Combined oxidative phosphorylation deficiency 48 0 trials
- Combined oxidative phosphorylation deficiency 51 0 trials
- Combined oxidative phosphorylation deficiency 52 0 trials
- Combined oxidative phosphorylation deficiency 53 0 trials
- Combined oxidative phosphorylation deficiency 54 0 trials
- Combined oxidative phosphorylation deficiency 55 0 trials
- Combined oxidative phosphorylation deficiency 56 0 trials
- Combined oxidative phosphorylation deficiency 57 0 trials
- Combined oxidative phosphorylation deficiency 58 0 trials
- Combined oxidative phosphorylation deficiency 59 0 trials
- Combined oxidative phosphorylation deficiency 60 0 trials
- Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 0 trials
- Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome 0 trials
- Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 0 trials
- Hypotonia with lactic acidemia and hyperammonemia 0 trials
- Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency 0 trials
- Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome 0 trials
- Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome 0 trials
- Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency 0 trials
- Mitochondrial proton-transporting ATP synthase complex deficiency 0 trials Sub-types →
- Severe X-linked mitochondrial encephalomyopathy 0 trials
-
4 sub-types
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3 0 trials
- Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4 0 trials
-
Hereditary spastic paraplegia 55 0 trials
-
Hereditary spastic paraplegia 77 0 trials
-
1 sub-type
-
Optic atrophy 3 0 trials
-
Spastic ataxia 3 0 trials
-
Spastic ataxia 4 0 trials
-
Spinocerebellar ataxia type 28 0 trials
Most studied deeper sub-types
-
New drug cocktail shows promise for rare muscle disease
Disease control CompletedThis phase 2 study tests a combination of two nucleoside drugs, doxecitine and doxribtimine, in 47 people with thymidine kinase 2 (TK2) deficiency, a rare genetic disorder that weakens muscles. Participants already receiving nucleoside therapy continue treatment to see if the dru…
Phase 2 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a High-Fat diet help kids with rare energy disorder?
Disease control CompletedThis study looked at whether a high-fat diet changes how children with mitochondrial disease burn energy. 36 children aged 5 to 21 were randomly assigned to eat either a normal or high-fat diet for a month, then switched. Researchers measured their resting energy use and body com…
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gene therapy shows promise for rare eye disease that causes blindness
Disease control CompletedThis Phase 3 trial tested a gene therapy called GS010 in 98 people with Leber hereditary optic neuropathy (LHON), a genetic condition that leads to rapid vision loss. Participants received injections of the therapy or a placebo into both eyes. The study measured changes in vision…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene therapy shows promise in Long-Term study for rare blindness
Disease control CompletedThis study followed 62 people with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that causes vision loss, for up to 5 years after they received a single gene therapy treatment called GS010. The goal was to see if the treatment remained safe and if any vis…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Gene therapy injection shows promise for rare eye disease
Disease control CompletedThis phase 3 trial tested a single injection of GS010 gene therapy in 39 people with Leber Hereditary Optic Neuropathy (LHON) who had vision loss for 6 months or less. The treatment aims to improve vision by delivering a working copy of the ND4 gene to the eye. Results measured c…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy shows promise for rare eye disease causing blindness
Disease control CompletedThis study tested a one-time gene therapy injection, GS010, in 37 adults with Leber Hereditary Optic Neuropathy (LHON), a genetic condition that causes rapid vision loss. Participants had vision loss for 6 to 12 months before treatment. The goal was to see if the therapy could im…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy for inherited blindness passes early safety check
Disease control CompletedThis study tested a gene therapy called GS010 in 19 adults with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that causes rapid vision loss. The main goal was to see if the treatment is safe and tolerable at different doses. The therapy uses a harmless vi…
Phase 1/2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug aims to help mitochondrial disease patients walk farther
Disease control CompletedThis Phase 3 trial tested a daily injection called elamipretide in 102 adults with primary mitochondrial myopathy, a genetic condition that causes muscle weakness and fatigue. Participants received either the drug or a placebo for 48 weeks. The main goal was to see if the drug co…
Phase 3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New study tracks daily life impact of rare eye disease
Knowledge-focused CompletedThis study looked at 44 people with a rare inherited eye condition called Leber Hereditary Optic Neuropathy (LHON) that causes vision loss. Researchers reviewed medical records and asked participants about their vision, health, and quality of life. The goal was to better understa…
Sponsor: GenSight Biologics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Blood biomarkers may help avoid unnecessary surgery in boys with testicle issues
Knowledge-focused CompletedThis study looked at tiny molecules in the blood called miRNAs to see if they could help doctors tell apart two similar conditions in boys: undescended testicles (which need surgery) and retractile testicles (which usually get better on their own). Researchers took blood samples …
Sponsor: Dr. Mevlüt Keleş • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Coenzyme Q10 showdown: new formula may boost absorption
Knowledge-focused CompletedThis study tested how well two different coenzyme Q10 supplements are absorbed into the blood after a single dose. Twenty-five healthy adults aged 50-65 took each product in a crossover design. The goal was to see if a new experimental formula (BMT® coenzyme Q10) leads to higher …
Sponsor: University of Primorska • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Could a single DNA test solve the mystery of rare brain diseases in kids?
Knowledge-focused CompletedThis study looked at whether whole genome sequencing (a complete read of a person's DNA) can help diagnose leukodystrophies, a group of rare brain diseases that are hard to identify. Researchers enrolled 236 children with white matter abnormalities on brain scans but no known gen…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
MS vision loss mystery: is it scarring or cell death?
Knowledge-focused CompletedThis study looked at 39 people with multiple sclerosis who have chronic vision problems. Researchers used eye exams, scans, and electrical tests to see if the vision loss is caused by nerve scarring (demyelination) or nerve cell death (degeneration). The goal is to better underst…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:45 UTC